References
1 Heikamp EB, Pui C-H. Next-Generation Evaluation and Treatment of Pediatric Acute Lymphoblastic Leukemia. J Pediatr . 2018;203:14-24.e2.
2 Pui C-H, Yang JJ, Hunger SP, et al. Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. J Clin Oncol . 2015;33(27):2938-2948.
3 Ding L-W, Sun Q-Y, Mayakonda A, et al. Mutational profiling of acute lymphoblastic leukemia with testicular relapse. J Hematol Oncol . 2017;10(1):65.
4 Kosucu P, Kul S, Gunes G, Yilmaz M, Ersoz S, Ozdemir F. Multiple relapses in extramedullary localization of acute lymphoblastic leukemia.Bratislava Med J . 2012;113(01):46-49.
5 Bhojwani D, Pui C-H. Relapsed childhood acute lymphoblastic leukaemia.Lancet Oncol . 2013;14(6):e205-e217.
6 KONDOH T, KURIBAYASHI K, TANAKA M, KOBAYASHI D, YANAGIHARA N, WATANABE N. CD7 promotes extramedullary involvement of the B-cell acute lymphoblastic leukemia line Tanoue by enhancing integrin β2-dependent cell adhesiveness. Int J Oncol . 2014;45(3):1073-1081.
7 Sun W, Malvar J, Sposto R, et al. Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study. Leukemia . 2018;32(11):2316-2325.
8 von Stackelberg A, Völzke E, Kühl J-S, et al. Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: A retrospective analysis of the ALL-REZ BFM Study Group. Eur J Cancer . 2011;47(1):90-97.
9 Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci . 1989;86(24):10024-10028.
10 Srivastava S, Riddell SR. Engineering CAR-T cells: Design concepts.Trends Immunol . 2015;36(8):494-502.
11 Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med . 2018;378(5):439-448.
12 Gardner RA, Finney O, Annesley C, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood . 2017;129(25):3322-3331..
13 Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial.Lancet . 2015;385(9967):517-528.
14 Curran KJ, Margossian SP, Kernan NA, et al. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. Blood . 2019;134(26):2361-2368.
15 Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant . 2019;25(4):625-638.
16 Weng J, Lai P, Qin L, et al. A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia. J Hematol Oncol . 2018;11(1):25.
17 Pui C-H, Evans WE. A 50-Year Journey to Cure Childhood Acute Lymphoblastic Leukemia. Semin Hematol . 2013;50(3):185-196.
18 Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med . 2017;376(9):836-847.
19 von Stackelberg A, Locatelli F, Zugmaier G, et al. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. J Clin Oncol . 2016;34(36):4381-4389.
20 Aldoss I, Song J, Stiller T, et al. Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia. Am J Hematol . 2017;92(9):858-865.
21 Jabbour E, Düll J, Yilmaz M, et al. Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. Am J Hematol . 2018;93(3):371-374.
22 Chen X, Wang Y, Ruan M, et al. Treatment of Testicular Relapse of B-cell Acute Lymphoblastic Leukemia With CD19-specific Chimeric Antigen Receptor T Cells. Clin Lymphoma Myeloma Leuk . 2020;20(6):366-370.
23 Talekar MK, Maude SL, Hucks GE, et al. Effect of chimeric antigen receptor-modified T (CAR-T) cells on responses in children with non-CNS extramedullary relapse of CD19+ acute lymphoblastic leukemia (ALL).J Clin Oncol . 2017;35(15_suppl):10507-10507.
24 Shah NN, Johnson BD, Schneider D, et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med . 2020;26(10):1569-1575.